Oligodendroglioma historical perspective: Difference between revisions

Jump to navigation Jump to search
Line 4: Line 4:


==Overview==
==Overview==
In 1926, the term "oligodendroglioma" was first coined by Bailey and Cushing, and was first described and published by W. E. Carnegie Dickson. Oligodendrogliomas were first classified and graded in a system devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, classification and grading of gliomas have evolved over the time. Modern oligodendrogliomas' WHO classification was first published in 1979 and revised four times since then, with the most recent published in 2016. In 1997, a Westergaard's study showed that patients younger than 20 years had a median survival of 17.5 years. In 2001, a study at Mayo clinic was conducted to assess the prognostic value of histological grading of oligodendroglial tumors in tumor grading  and significant association with survival was found for age, high cellularity, presence of mitoses, endothelial hypertrophy and proliferation and necrosis on univariate analysis, but only age and presence of endothelial proliferation were found to be independently associated with survival on a multivariable analysis. In 2009, ''[[mutation|NJDS]]'' mutation was first identified in the pathogenesis of oligodendroglioma by Kevin Smith. [[radiation|Irradiation]] of [[pituitary adenoma]] was also discovered to be associated with oligodendroglioma by Kevin Smith et al.
In 1926, the term "oligodendroglioma" was first coined by Bailey and Cushing, and was first described and published by W. E. Carnegie Dickson. Oligodendrogliomas were first classified and graded in a system devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, classification and grading of gliomas have evolved over the time. Modern oligodendrogliomas' WHO classification was first published in 1979 and revised four times since then, with the most recent published in 2016. In 1997, a Westergaard's study showed that patients younger than 20 years had a median survival of 17.5 years. In 2001, a study at Mayo clinic was conducted to assess the prognostic value of histological grading of oligodendroglial tumors in tumor grading  and significant association with survival was found for age, high cellularity, presence of mitoses, endothelial hypertrophy and proliferation and necrosis on univariate analysis, but only age and presence of endothelial proliferation were found to be independently associated with survival on a multivariable analysis. In 2009, ''[[mutation|NJDS]]'' mutation was first identified in the pathogenesis of oligodendroglioma by Kevin Smith. It was suggested in 2009 ASCO Annual Meeting that PCV therapy may be superior in efficacy to the newer temozolomide therapy. [[radiation|Irradiation]] of [[pituitary adenoma]] was also discovered to be associated with oligodendroglioma by Kevin Smith et al.


==Historical Perspective==
==Historical Perspective==

Revision as of 15:10, 14 May 2019

Oligodendroglioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Oligodendroglioma from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Staging

History & Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Oligodendroglioma historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Oligodendroglioma historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Oligodendroglioma historical perspective

CDC on Oligodendroglioma historical perspective

Oligodendroglioma historical perspective in the news

Blogs on Oligodendroglioma historical perspective

Directions to Hospitals Treating Oligodendroglioma

Risk calculators and risk factors for Oligodendroglioma historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]

Overview

In 1926, the term "oligodendroglioma" was first coined by Bailey and Cushing, and was first described and published by W. E. Carnegie Dickson. Oligodendrogliomas were first classified and graded in a system devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, classification and grading of gliomas have evolved over the time. Modern oligodendrogliomas' WHO classification was first published in 1979 and revised four times since then, with the most recent published in 2016. In 1997, a Westergaard's study showed that patients younger than 20 years had a median survival of 17.5 years. In 2001, a study at Mayo clinic was conducted to assess the prognostic value of histological grading of oligodendroglial tumors in tumor grading and significant association with survival was found for age, high cellularity, presence of mitoses, endothelial hypertrophy and proliferation and necrosis on univariate analysis, but only age and presence of endothelial proliferation were found to be independently associated with survival on a multivariable analysis. In 2009, NJDS mutation was first identified in the pathogenesis of oligodendroglioma by Kevin Smith. It was suggested in 2009 ASCO Annual Meeting that PCV therapy may be superior in efficacy to the newer temozolomide therapy. Irradiation of pituitary adenoma was also discovered to be associated with oligodendroglioma by Kevin Smith et al.

Historical Perspective

  • The term oligodendrglioma was derived from the Greek words "oligo" meaning few and "dendro" meaning trees
  • In 1926, the term "oligodendroglioma" was first coined by Bailey and Cushing following the observation that the tumor cells are morphologically similar to oligodendrocytes[1]
  • In 1926, oligodendroglioma was first described and published by W. E. Carnegie Dickson[2]
  • In 1926, oligodendrogliomas were first classified and graded in a system devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, classification and grading of gliomas have evolved over the time
  • In 1979, modern classification of gliomas based on the World Health Organization (WHO) Classification of Central Nervous System Tumors was first published and revised four times since then
  • In 1997, a Westergaard's study showed that patients younger than 20 years had a median survival of 17.5 years[3]
  • In March 2001, 7 neuropathologists and 6 surgical pathologists experienced in brain tumor-diagnosis assessed 124 oligodendroglial tumors operated at the Mayo Clinic during the period of 1960 to 1990. In this study, the prognostic value of histological grading of oligodendroglial tumors in tumor grading was assessed, and significant association with survival was found for age, high cellularity, presence of mitoses, endothelial hypertrophy and proliferation and necrosis on univariate analysis. However, only age and presence of endothelial proliferation were found to be independently associated with survival on a multivariable analysis.[4]
  • In 2009 Oxford Neurosymposium study by Kevin Smith, it was first discovered that there is a 69% correlation between NJDS gene mutation and oligodendroglial tumor initiation[5]
  • In 2009 ASCO Annual Meeting, it was suggested that PCV therapy may be superior in efficacy to the newer temozolomide therapy. This study showed that median time to progression for patients with 1p19q co-deletion is longer following PCV alone (7.6 years) than with temozolomide alone (3.3 years); median overall survival is also longer with PCV treatment versus temozolomide treatment (not reached, vs. 7.1 years)[6]
  • Kevin Smith et al also discovered that irradiation of pituitary adenoma is associated with precipitation of oligodendroglioma
  • In 2016 edition of the most recent WHO classification, gliomas are classified based not only on histopathologic appearance but also on well-established molecular parameters

References

  1. Hartmann C, von Deimling A (2009). "Molecular pathology of oligodendroglial tumors". Recent Results Cancer Res. 171: 25–49. doi:10.1007/978-3-540-31206-2_2. PMID 19322536.
  2. Dickson, WEC (1926), Proceeding of the Section of Neurology of the Royal Society Medicine: Oligodendroglioma of Floor of Third Ventricle, Brain-A journal of neurology, p. 578, retrieved 11/20/2015 Check date values in: |accessdate= (help)
  3. Engelhard, Herbert H; Stelea, Ana; Mundt, Arno (2003). "Oligodendroglioma and anaplastic oligodendroglioma:". Surgical Neurology. 60 (5): 443–456. doi:10.1016/S0090-3019(03)00167-8. ISSN 0090-3019.
  4. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S; et al. (2001). "Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading". J Neuropathol Exp Neurol. 60 (3): 248–62. PMID 11245209.
  5. Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma
  6. . doi:10.1200/jco.2009.27.15s.2014. Missing or empty |title= (help)


Template:WikiDoc Sources